Why CONNEQT
A first-of-its-kind Arterial Health Assessment
CONNEQT is the first clinical-grade arterial assessment that brings professional-level arterial health insights into your home.
Built with 50 years of cardiovascular science and trusted by cardiologists, it goes far beyond traditional blood pressure—tracking your central blood pressure, arterial stiffness, pulse waveforms, and more. Born from breakthrough SphygmoCor® technology, and refined for real-life wellness, CONNEQT delivers life-saving insights—before symptoms show.
Now is the time to take the next step for your heart.
- You want to know that you’re OK.
- You're concerned about hypertension and how your arterial health impacts your heart, kidneys, and brain.
- You want more health insights than provided by traditional blood pressure devices.
- You want insights you can trust—clear, personalized, accurate, and reliable.
- You’re looking for a device backed by cardiologists, validated by research, and proven in clinical trials.
- You want to track your cardiovascular health over time at home.
- You’re making lifestyle changes and want to measure your progress.
- Whether it's fatigue, poor circulation, heart failure, long Covid, menopause, or other warning signs - you're ready to take a closer look at your heart health.
No matter where you are in your heart health journey, CONNEQT's Arterial Health Assessment helps you take control of your future.
How CONNEQT compares to other screenings
| Test | Price | Heart Risk Assessed | # of Reports | In-Home Test |
|---|---|---|---|---|
| Full-Body MRI Scan | Up to $2,500 | None | One-Time | No |
| Cleerly Heart Scan | Up to $1,500 | Detailed coronary artery plaque analysis | One-Time | No |
| Coronary Calcium Scan | Up to $500 | Measures calcium buildup in arteries | One-Time | No |
| DEXA Scan | Up to $500 | None | One-Time | No |
| CONNEQT Arterial Health Assessment | $350 | Quantifies risk of heart attack & stroke | Two (2) | Yes |
| Carotid Artery Screening | Up to $300 | Detects blockages in carotid arteries | One-Time | No |
| Lipid Panel | Up to $40 | Measures cholesterol and triglycerides levels | One-Time | No |
Better Prediction
Central blood pressure measurements are 69% more predictive of heart events than traditional blood pressure readings—even when arm-cuff readings appear normal*.
Central blood pressures have been shown to correlate more strongly with vascular disease than do routine peripheral blood pressure measurements.
Cleveland Clinic
Central
Brachial
Subendocardial
Medical Grade Heart Measurement
Central Pulse 
Augmentation
Augmentation“Gold Standard” Arterial Biomarkers
Globally recognized “gold standard” technology and reference devices for measuring central blood pressure and arterial stiffness**
Hypertension Research, Journal of Hypertension, Hypertension (American Heart Association guidelines/statements) Artery Society.
More Predictive Data = More Proactive Health
Research-Backed Health Insights
Traditional blood pressure readings only tell part of the story. The Pulse arterial health monitor uses Pulse Wave Analysis (PWA) to measure key vascular biomarkers that predict cardiovascular (CV) risk before symptoms appear.
Results & Clinical Interpretation of CONNEQT Arterial Health Biomarkers
| Measurement | Central Blood Pressure | Central Pulse Pressure | Pulse Pressure Amplification | Augmentation Pressure | Augmentation Index |
|---|---|---|---|---|---|
| Threshold | >130 mmHg | >50 mmHg | <130% | Each 10 mmHg increase in AP | Each 10 % increase in Alx |
| Risk of Cardiovascular Events | 3x increased risk of cardiovascular events* |
2-3x increased risk of cardiovascular events* |
2-3x increased risk of cardiovascular events*> |
30% Increase risk of cardiovascular events* |
35-40% Increase risk of cardiovascular events* |
*Cardiovascular events are defined as a myocardial infarction, coronary revascularization, stroke, heart failure, or cardiovascular mortality.
A 4-mmHg reduction in central pressure can lower cardiovascular risk by 20%. Reductions in arterial stiffness have been shown with ACE-inhibitors, calcium channel blockers, statins, PCSK9 inhibitors, and SGLT2 inhibitors.
By tracking these biomarkers, the Pulse helps detect hidden risks, optimize heart health, and empower better cardiovascular decisions.
The Gold Standard in Arterial Health—Trusted Worldwide
Powered by SphygmoCor®
CONNEQT Pulse is powered by our patented SphygmoCor® technology, the gold standard in arterial health assessment, used by leading cardiovascular researchers, pharmaceutical companies, and healthcare institutions worldwide.
- Used by Mayo Clinic, Cleveland Clinic, Weill Cornell, and top research hospitals.
- Integrated into clinical trials for major pharmaceutical companies.
- Validated by over 2700 peer reviewed research papers on arterial health and cardiovascular risk assessment.
Cited in Over 2700 Peer-Reviewed Publications
Our SphygmoCor® Technology by the Numbers
Top 20
All “Top 20 Hospitals” use SphygmoCor technology to measure central blood pressure (cBP)
2,700+
SphygmoCor technology has supported studies that have resulted in over 2,700 peer-reviewed publications.
8/10
8 out of top 10 Pharma companies have used SphygmoCor technology in their clinical trials
11,000
Over 11,000 patients have been tested with SphygmoCor technology in pharmaceutical trials
Research Backed. Science Driven
In a study of 1100 patients central pulse pressure was a powerful predictor of major cardiovascular events, while brachial blood pressure was not
Jankowski et al, Hypertension, 2008
Trusted by Leading Pharma
Trustworthy Third Party Validation
This product meets the Validated Device Listing (VDL) criteria (as listed on validatebp.org) for validation of clinical accuracy, based on the independent review and acceptance of documentation submitted by the manufacturer.
Backed by Over 50 Years of Research, 20+ Years of Commercial Use, and 5x FDA-Clearances to Date***
*High Central Pulse Pressure Is Independently Associated With Adverse Cardiovascular Outcome: The Strong Heart Study. Journal of the American College of Cardiology - Volume 54, Number 18
**Hypertension Research (2014), Journal of Hypertension (review articles), Hypertension (American Heart Association guidelines/statements) re: SphygmoCorⓇ c-PWV technology
***SphygmoCor technology.